Extending transdermal nicotine therapy from 8 to 24 weeks increases point-prevalence abstinence at 24 but not 52 weeks

Anne M. Joseph

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Extending transdermal nicotine therapy from 8 to 24 weeks increases point-prevalence abstinence at 24 but not 52 weeks'. Together they form a unique fingerprint.